These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 25778855)

  • 1. [Comparative dissolution test of modified release pharmaceutical products for potassium replacement].
    Herényi B; Mikó P
    Orv Hetil; 2015 Mar; 156(12):479-82. PubMed ID: 25778855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Dissolution Medium pH and Simulated Gastrointestinal Contraction on Drug Release From Nifedipine Extended-Release Tablets.
    Gao Z; Ngo C; Ye W; Rodriguez JD; Keire D; Sun D; Wen H; Jiang W
    J Pharm Sci; 2019 Mar; 108(3):1189-1194. PubMed ID: 30343136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of In Vitro-In Vivo Correlation for Potassium Chloride Extended Release Tablet Formulation Using Urinary Pharmacokinetic Data.
    Mittapalli RK; Marroum P; Qiu Y; Apfelbaum K; Xiong H
    Pharm Res; 2017 Jul; 34(7):1527-1533. PubMed ID: 28512718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison of two commercial potassium chloride tablets for slow-release in an in vitro dissolution test].
    Wu PC; Huang YB; Chang SJ; Ko HM; Tsai YH
    Gaoxiong Yi Xue Ke Xue Za Zhi; 1992 Mar; 8(3):161-7. PubMed ID: 1560473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro dissolution of proton-pump inhibitor products intended for paediatric and geriatric use in physiological bicarbonate buffer.
    Liu F; Shokrollahi H
    Int J Pharm; 2015 May; 485(1-2):152-9. PubMed ID: 25746736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting the gastrointestinal behaviour of modified-release products: utility of a novel dynamic dissolution test apparatus involving the use of bicarbonate buffers.
    Merchant HA; Goyanes A; Parashar N; Basit AW
    Int J Pharm; 2014 Nov; 475(1-2):585-91. PubMed ID: 25195730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and in vivo evaluation of novel monolithic controlled release compositions of galantamine hydrobromide as against reservoir technology.
    Khatavkar UN; Shimpi SL; Kumar KJ; Deo KD
    Pharm Dev Technol; 2013; 18(5):1148-58. PubMed ID: 21770841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A canine biorelevant dissolution method for predicting in vivo performance of orally administered sustained release matrix tablets.
    Walsh PL; Bothe JR; Bhardwaj S; Hu M; Nofsinger R; Xia B; Persak S; Pennington J; Bak A
    Drug Dev Ind Pharm; 2016; 42(5):836-44. PubMed ID: 26339722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a novel osmotically driven drug delivery system for weakly basic drugs.
    Guthmann C; Lipp R; Wagner T; Kranz H
    Eur J Pharm Biopharm; 2008 Jun; 69(2):667-74. PubMed ID: 18226884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Constant potassium chloride release from microporous membrane-coated tablets prepared with aqueous colloidal polymer dispersions.
    Bodmeier R; Paeratakul O
    Pharm Res; 1991 Mar; 8(3):355-9. PubMed ID: 2052524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An in vitro dissolution test for slow release potassium chloride tablets.
    Cartwright AC; Shah C
    J Pharm Pharmacol; 1977 Jun; 29(6):367-9. PubMed ID: 18575
    [No Abstract]   [Full Text] [Related]  

  • 13. Simulating Different Dosing Scenarios for a Child-Appropriate Valproate ER Formulation in a New Pediatric Two-Stage Dissolution Model.
    Karkossa F; Krueger A; Urbaniak J; Klein S
    AAPS PharmSciTech; 2017 Feb; 18(2):309-316. PubMed ID: 27909943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Release characteristics and in vitro-in vivo correlation of pulsatile pattern for a pulsatile drug delivery system activated by membrane rupture via osmotic pressure and swelling.
    Lin HL; Lin SY; Lin YK; Ho HO; Lo YW; Sheu MT
    Eur J Pharm Biopharm; 2008 Sep; 70(1):289-301. PubMed ID: 18539015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single blind normal volunteer bioavailability study of a new microencapsulated potassium chloride tablet compared with two reference potassium formulations.
    Caplain H; Dahan R; Pamphile R; Thebault JJ
    Eur J Drug Metab Pharmacokinet; 1991; 16(3):241-4. PubMed ID: 1814742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of an in vitro dissolution and absorption system to evaluate oral absorption of two weak bases in pH-independent controlled-release formulations.
    Sugawara M; Kadomura S; He X; Takekuma Y; Kohri N; Miyazaki K
    Eur J Pharm Sci; 2005 Sep; 26(1):1-8. PubMed ID: 15961297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of xanthan gum based sustained release matrix tablets containing highly water-soluble propranolol HCl.
    Ali A; Iqbal M; Akhtar N; Khan HM; Ullah A; Uddin M; Khan MT
    Acta Pol Pharm; 2013; 70(2):283-9. PubMed ID: 23614284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo evaluation of potassium chloride sustained release formulation prepared with saturated polyglycolyed glycerides matrices.
    Wu PC; Tsai MJ; Huang YB; Chang JS; Tsai YH
    Int J Pharm; 2002 Aug; 243(1-2):119-24. PubMed ID: 12176300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selection of the most suitable dissolution method for an extended release formulation based on IVIVC level A obtained on cynomolgus monkey.
    Scheubel E; Adamy L; Hoffart V; Cardot JM
    Drug Dev Ind Pharm; 2010 Nov; 36(11):1320-9. PubMed ID: 20849348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of an In Vitro Drug Release Method to Enable In Vitro-In Vivo Correlation of Potassium Chloride Extended-Release Tablets.
    Qiu Y; Zhu DA; Apfelbaum K; Zu H; Xiong H
    Mol Pharm; 2022 Nov; 19(11):4191-4198. PubMed ID: 36049021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.